Byotrol making progress and cutting losses

BYOTROL, the Daresbury company behind the anti-microbial product of the same name, says its has grown sales and reduced losses this financial year.

The AIM company, which sells in to the food, industrial, healthcare and consumer sectors, said “good progress”  had been made in the year to March 31.
 
It said it is expecting consumer revenues to accelerate in the next financial year in the US in particular as progress is made towards getting regulartory approval.

In a trading update ahead of the results which will be posted in July, the board said it is expecting sales for the year to be in the region of £3.2m (£2.75m in 2014) and the loss before interest taxation and depreciation to be approximately £425,000, compared with a £1.1m loss in the previous year.
 
Byotrol said: “We continue to invest heavily in R&D, having invested well over £400k in the year.  Much of this spend has been devoted to updating our technologies in preparation for the new EU regulatory regime for biocides.  

“This has involved considerable re-formulation work to our core range, work which is progressing very well but is ongoing.  We have recently been granted a patent for our new consumer surface care product and have filed a patent for a new skincare technology which we believe has significant potential across our whole business.

“We remain committed to a strategy of product development to increase sales and expect to achieve monthly break even in the latter half of the current financial year.”

Byotrol has also been working on building new commercial partnerships, mostly with bigger businesses. One such deal is a joint marketing agreement with ISS Facility Services – Healthcare,  part of the ISS group, one of the world’s largest facility services providers, where the two firms will target surface care opportunities in the NHS.